Regulus Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Regulus Therapeutics

07/05/2024 17:40

* Regulus Therapeutics Inc  RGLS.OQ   RGLS.O  is expected
to show
no change in quarterly revenue when it reports  results on May 9
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Regulus Therapeutics Inc
is
for a loss of 22 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 2.1%
in the last three months. ​
    * Wall Street's median 12-month price target for Regulus
Therapeutics Inc is $6.00​, above​ its last closing price
of $2.43. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.40       -0.39      -0.40     Missed  -1.3
 Sep. 30 2023  -0.41       -0.40      -0.40     Met     -0.8
 Jun. 30 2023  -0.41       -0.41      -0.37     Beat    9.8​
 Mar. 31 2023  -0.44       -0.44      -0.42     Beat    3.8
 ​​Jan.                    -0.51      -0.40     Beat    21.6
 1 0001                                                 
 Sep. 30 2022  -0.49       -0.49      -0.50     Missed  -2​
 Jun. 30 2022  -0.49       -0.48      -0.50     Missed  -3.1
 Mar. 31 2022  -0.56       -0.53      -0.50     Beat    6.2
 This summary was machine generated May 7 at 16:40 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)